248 related articles for article (PubMed ID: 16028357)
1. Impact of P-glycoprotein-mediated intestinal efflux kinetics on oral bioavailability of P-glycoprotein substrates.
Kwon H; Lionberger RA; Yu LX
Mol Pharm; 2004; 1(6):455-65. PubMed ID: 16028357
[TBL] [Abstract][Full Text] [Related]
2. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.
Darwich AS; Neuhoff S; Jamei M; Rostami-Hodjegan A
Curr Drug Metab; 2010 Nov; 11(9):716-29. PubMed ID: 21189140
[TBL] [Abstract][Full Text] [Related]
3. Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge.
Yu XY; Lin SG; Zhou ZW; Chen X; Liang J; Liu PQ; Duan W; Chowbay B; Wen JY; Li CG; Zhou SF
Curr Drug Metab; 2007 May; 8(4):325-40. PubMed ID: 17504222
[TBL] [Abstract][Full Text] [Related]
4. Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1.
Luo FR; Paranjpe PV; Guo A; Rubin E; Sinko P
Drug Metab Dispos; 2002 Jul; 30(7):763-70. PubMed ID: 12065434
[TBL] [Abstract][Full Text] [Related]
5. Dual-functional Brij-S20-modified nanocrystal formulation enhances the intestinal transport and oral bioavailability of berberine.
Xiong W; Sang W; Linghu KG; Zhong ZF; Cheang WS; Li J; Hu YJ; Yu H; Wang YT
Int J Nanomedicine; 2018; 13():3781-3793. PubMed ID: 29988733
[TBL] [Abstract][Full Text] [Related]
6. Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo.
Collett A; Tanianis-Hughes J; Hallifax D; Warhurst G
Pharm Res; 2004 May; 21(5):819-26. PubMed ID: 15180340
[TBL] [Abstract][Full Text] [Related]
7. High-dose etoposide formulations do not saturate intestinal P-glycoprotein: Development, stability, and pharmacokinetics in Sprague-Dawley rats.
Al-Ali AAA; Sandra L; Versweyveld D; Pijpers I; Dillen L; Vermeulen A; Snoeys J; Holm R; Nielsen CU
Int J Pharm; 2020 Jun; 583():119399. PubMed ID: 32376439
[TBL] [Abstract][Full Text] [Related]
8. Reversible inhibition of efflux transporters by hydrogel microdevices.
Levy ES; Samy KE; Lamson NG; Whitehead KA; Kroetz DL; Desai TA
Eur J Pharm Biopharm; 2019 Dec; 145():76-84. PubMed ID: 31639417
[TBL] [Abstract][Full Text] [Related]
9. Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein.
Tachibana T; Kato M; Takano J; Sugiyama Y
Curr Drug Metab; 2010 Nov; 11(9):762-77. PubMed ID: 21189139
[TBL] [Abstract][Full Text] [Related]
10. The pharmacological role of P-glycoprotein in the intestinal epithelium.
Van Asperen J; Van Tellingen O; Beijnen JH
Pharmacol Res; 1998 Jun; 37(6):429-35. PubMed ID: 9695116
[TBL] [Abstract][Full Text] [Related]
11. Role of P-glycoprotein in the intestinal absorption of glabridin, an active flavonoid from the root of Glycyrrhiza glabra.
Cao J; Chen X; Liang J; Yu XQ; Xu AL; Chan E; Wei D; Huang M; Wen JY; Yu XY; Li XT; Sheu FS; Zhou SF
Drug Metab Dispos; 2007 Apr; 35(4):539-53. PubMed ID: 17220245
[TBL] [Abstract][Full Text] [Related]
12. Factors and dosage formulations affecting the solubility and bioavailability of P-glycoprotein substrate drugs.
Murakami T; Bodor E; Bodor N
Expert Opin Drug Metab Toxicol; 2021 May; 17(5):555-580. PubMed ID: 33703995
[No Abstract] [Full Text] [Related]
13. Physiologically-Based Pharmacokinetic Modeling Approach to Predict Rifampin-Mediated Intestinal P-Glycoprotein Induction.
Yamazaki S; Costales C; Lazzaro S; Eatemadpour S; Kimoto E; Varma MV
CPT Pharmacometrics Syst Pharmacol; 2019 Sep; 8(9):634-642. PubMed ID: 31420942
[TBL] [Abstract][Full Text] [Related]
14. Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in situ and in vitro.
Adachi Y; Suzuki H; Sugiyama Y
Pharm Res; 2003 Aug; 20(8):1163-9. PubMed ID: 12948013
[TBL] [Abstract][Full Text] [Related]
15. Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine.
Bolger MB; Lukacova V; Woltosz WS
AAPS J; 2009 Jun; 11(2):353-63. PubMed ID: 19434502
[TBL] [Abstract][Full Text] [Related]
16. Targeting intestinal transporters for optimizing oral drug absorption.
Varma MV; Ambler CM; Ullah M; Rotter CJ; Sun H; Litchfield J; Fenner KS; El-Kattan AF
Curr Drug Metab; 2010 Nov; 11(9):730-42. PubMed ID: 21189135
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs.
Fromm MF
Int J Clin Pharmacol Ther; 2000 Feb; 38(2):69-74. PubMed ID: 10706193
[TBL] [Abstract][Full Text] [Related]
18. Intestinal P-glycoprotein inhibitors, benzoxanthone analogues.
Chae SW; Lee J; Park JH; Kwon Y; Na Y; Lee HJ
J Pharm Pharmacol; 2018 Feb; 70(2):234-241. PubMed ID: 29238994
[TBL] [Abstract][Full Text] [Related]
19. Role of P-glycoprotein in drug disposition.
Tanigawara Y
Ther Drug Monit; 2000 Feb; 22(1):137-40. PubMed ID: 10688277
[TBL] [Abstract][Full Text] [Related]
20. Resolution of P-glycoprotein and non-P-glycoprotein effects on drug permeability using intestinal tissues from mdr1a (-/-) mice.
Stephens RH; O'Neill CA; Bennett J; Humphrey M; Henry B; Rowland M; Warhurst G
Br J Pharmacol; 2002 Apr; 135(8):2038-46. PubMed ID: 11959808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
